3,000 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by Aquila Investment Management LLC

Aquila Investment Management LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNAFree Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 3,000 shares of the company’s stock, valued at approximately $298,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Moderna by 0.7% in the third quarter. Vanguard Group Inc. now owns 27,658,449 shares of the company’s stock valued at $2,856,841,000 after acquiring an additional 196,012 shares during the period. Geode Capital Management LLC boosted its stake in Moderna by 1.3% in the first quarter. Geode Capital Management LLC now owns 6,244,957 shares of the company’s stock valued at $957,063,000 after acquiring an additional 77,265 shares during the period. Wellington Management Group LLP boosted its stake in Moderna by 9.3% in the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock valued at $579,572,000 after acquiring an additional 476,201 shares during the period. Morgan Stanley boosted its stake in Moderna by 19.1% in the fourth quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock valued at $752,133,000 after acquiring an additional 670,284 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Moderna by 77.3% during the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after buying an additional 1,690,341 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 544 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the sale, the insider now directly owns 9,267 shares in the company, valued at $917,896.35. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $107.12, for a total value of $1,606,800.00. Following the completion of the transaction, the director now owns 2,071,931 shares of the company’s stock, valued at $221,945,248.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Shannon Thyme Klinger sold 544 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the completion of the transaction, the insider now directly owns 9,267 shares of the company’s stock, valued at approximately $917,896.35. The disclosure for this sale can be found here. Insiders have sold a total of 94,954 shares of company stock worth $9,966,476 over the last ninety days. Company insiders own 15.70% of the company’s stock.

Analyst Ratings Changes

MRNA has been the subject of several analyst reports. Canaccord Genuity Group boosted their price objective on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective for the company in a research report on Tuesday, January 2nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Thursday. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $126.49.

Check Out Our Latest Research Report on Moderna

Moderna Stock Down 1.7 %

Shares of MRNA stock opened at $105.14 on Friday. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $163.24. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. The firm’s 50 day moving average price is $99.86 and its two-hundred day moving average price is $93.57.

Moderna (NASDAQ:MRNAGet Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. The firm had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business’s revenue for the quarter was down 44.9% on a year-over-year basis. During the same period last year, the firm earned $3.61 earnings per share. As a group, equities analysts forecast that Moderna, Inc. will post -7.48 EPS for the current year.

Moderna Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Read More

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.